Cancer Vaccines Harnessing the Immune System for Prevention and Treatment

Milad Ashrafizadeh^*
*Correspondence: Milad Ashrafizadeh, Department of General Surgery, Shenzhen University, Shenzhen, Guangdong 518055, China, Email:

Keywords

Cancer vaccines • Prevention and treatment • Immune system

Introduction

Unlike traditional vaccines that aim to prevent infectious diseases, cancer vaccines operate on a different principle. They stimulate the immune system to recognize and attack cancer cells specifically. The immune system, when functioning optimally, can distinguish between healthy cells and those that pose a threat, including cancerous ones. However, cancer cells often evade detection by the immune system or suppress its response, allowing them to proliferate unchecked. Cancer vaccines come in various forms, but they generally fall into two categories: preventive (prophylactic) vaccines and therapeutic vaccines [1].

Literature Review

Preventive (prophylactic) vaccines

These vaccines aim to prevent the development of cancer by targeting infectious agents known to cause specific types of cancer. Human Papillomavirus (HPV) vaccines are a prime example. HPV infection is a major risk factor for cervical cancer, and vaccines like Gardasil and Cervarix work by targeting specific strains of the virus. By preventing HPV infection, these vaccines reduce the likelihood of cervical cancer [2].

Therapeutic vaccines

Therapeutic cancer vaccines, on the other hand, are designed for individuals who have already been diagnosed with cancer. These vaccines stimulate the immune system to recognize and attack cancer cells, acting as an adjunct to conventional treatments like surgery, chemotherapy, and radiation therapy [3].

Mechanisms of action

Cancer vaccines operate by leveraging the immune system's ability to identify and eliminate abnormal cells. The immune response against cancer involves two main components: the innate immune system and the adaptive immune system.

Innate immune system

The innate immune system provides a rapid, non-specific defense against foreign invaders. Cancer cells can release signals that attract innate immune cells, such as macrophages and natural killer cells, to the site of the tumor. Cancer vaccines may enhance this process by promoting the activation and recruitment of these innate immune cells [4].

Adaptive immune system

The adaptive immune system, a more specialized and targeted branch of immunity, involves T cells and B cells. Cancer vaccines aim to activate and train T cells to recognize specific antigens present on cancer cells. Antigens are molecules that trigger an immune response. Tumor-specific antigens, such as mutated proteins, are the focus of many cancer vaccine strategies.

Types of cancer vaccines

Several types of cancer vaccines are under development, each with its unique approach to harnessing the immune system. Some of the prominent categories include:

Peptide-based vaccines

These vaccines use short chains of amino acids (peptides) derived from tumor-specific antigens. By presenting these peptides to the immune system, the vaccine aims to stimulate T cells to recognize and attack cancer cells displaying the same antigens.

Whole cell vaccines

Whole cell vaccines use entire cancer cells; either lives or inactivated, to trigger an immune response. These cells may be obtained from the patient's own tumor (autologous) or from another source (allogeneic). Whole cell vaccines expose the immune system to a broad array of tumor antigens, increasing the likelihood of an effective response [5].

DNA/RNA-based vaccines

DNA or RNA-based vaccines introduce genetic material encoding tumorspecific antigens into the body. Once inside cells, this genetic material instructs the cell to produce the antigen, prompting an immune response. This approach is versatile and allows for the inclusion of multiple antigens.

Viral vector vaccines

Viral vectors often modified viruses that do not cause illness, can be used to deliver tumor-specific antigens into cells. The modified virus acts as a vehicle, introducing the antigen to the immune system and triggering a targeted response against cancer cells [6].

Current developments in cancer vaccines

The field of cancer vaccines has witnessed significant advancements in recent years, with ongoing research and clinical trials contributing to their evolution. Notable developments include:

MRNA vaccines

The success of mRNA vaccines in preventing infectious diseases, such as COVID-19, has sparked interest in applying this technology to cancer vaccines. mRNA vaccines deliver genetic instructions to cells, directing the production of tumor-specific antigens. Companies like Moderna and BioNTech are actively exploring mRNA-based cancer vaccines in clinical trials.

Discussion

Personalized cancer vaccines

Personalized cancer vaccines, also known as neoantigen vaccines, take advantage of the unique genetic mutations present in an individual's cancer cells. By sequencing the patient's tumor DNA, researchers can identify neoantigens – antigens that arise from mutations. Vaccines are then tailored to stimulate an immune response against these specific neoantigens, potentially offering a highly personalized and effective treatment strategy.

Combination therapies

Researchers are increasingly exploring combination therapies that combine cancer vaccines with other immunotherapies or traditional treatments. For instance, combining a cancer vaccine with immune checkpoint inhibitors, which unleash the immune system's full potential, has shown promise in enhancing treatment efficacy.

Challenges and limitations

While cancer vaccines hold tremendous promise, several challenges and limitations must be addressed for their widespread success:

Tumor heterogeneity

Cancer is characterized by its heterogeneity – the presence of diverse cell populations within a tumor. Developing a vaccine that targets all relevant antigens across this heterogeneity remains a formidable challenge. Tumor evolution and the emergence of resistant cell populations further complicate the design of effective vaccines.

Immune evasion mechanisms

Cancer cells employ various strategies to evade the immune system, such as down regulating antigen presentation or expressing immune checkpoint molecules. These mechanisms can limit the effectiveness of cancer vaccines. Combining vaccines with agents that disrupt these evasion strategies is an active area of research.

Safety concerns

Ensuring the safety of cancer vaccines is paramount. Some early vaccine candidates faced challenges related to toxicity and adverse effects. Striking the right balance between stimulating a robust immune response and avoiding harm to healthy tissues is crucial in vaccine development.

Logistics and cost

The production, storage, and administration of cancer vaccines pose logistical challenges. Additionally, the cost of developing and manufacturing personalized cancer vaccines, in particular, raises economic considerations and access issues for patients.

Future prospects

Despite the challenges, the landscape of cancer vaccines is evolving rapidly, with several promising avenues for the future:

Expanded use of neoantigen vaccines

As technology advances and genomic profiling becomes more accessible, the use of neoantigen vaccines is likely to expand. These personalized vaccines have the potential to target the unique characteristics of each patient's cancer, paving the way for more effective and tailored treatments.

Enhanced combinatorial approaches

Combining cancer vaccines with other immunotherapies or traditional treatments is expected to become more prevalent. Synergistic effects may be achieved by simultaneously targeting multiple aspects of the immune response and the tumor microenvironment.

Overcoming immune evasion mechanisms

Researchers are actively investigating ways to overcome the immune evasion mechanisms employed by cancer cells. Strategies such as combining vaccines with immune checkpoint inhibitors or targeting specific signaling pathways aim to enhance the immune response against cancer.

Advancements in MRNA technology

The success of mRNA vaccines in infectious diseases has opened new possibilities for cancer vaccine development. Ongoing research in this area may lead to more effective and versatile mRNA-based cancer vaccines.

Conclusion

Cancer vaccines represent a groundbreaking approach to cancer prevention and treatment by harnessing the power of the immune system. As research and development efforts continue, the field holds immense potential for transforming the landscape of cancer care. From preventive vaccines targeting specific infections to personalized neoantigen vaccines tailored to individual patients, the diversity of approaches underscores the complexity of the battle against cancer. While challenges persist, ongoing advancements, such as the use of mRNA technology and combinatorial therapies, offer hope for overcoming obstacles and improving the efficacy of cancer vaccines. As we look to the future, the integration of these innovative strategies into mainstream oncology may usher in a new era where cancer vaccines play a pivotal role in our collective fight against this formidable disease.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Blandin, Anne-Florence, Guillaume Renner, Maxime Lehmann and Isabelle Lelong-Rebel, et al. "β1 integrins as therapeutic targets to disrupt hallmarks of cancer." Front Pharmacol 6 (2015): 279.

   Google Scholar, Crossref, Indexed at

2. Gamerith, Gabriele, Marcel Kloppenburg, Finn Mildner and Arno Amann, et al. "Molecular characteristics of radon associated lung cancer highlights MET alterations." Cancers 14 (2022): 5113.

   Google Scholar, Crossref, Indexed at

3. Bodén, Embla, Fanny Sveréus, Franziska Olm and Sandra Lindstedt. "A systematic review of Mesenchymal Epithelial Transition factor (MET) and its impact in the development and treatment of non-small-cell lung cancer." Cancers 15 (2023): 3827.

   Google Scholar, Crossref, Indexed at

4. Van Herpe, Filip and Eric Van Cutsem. "The role of cMET in gastric cancer—A review of the literature." Cancers 15 (2023): 1976.

   Google Scholar, Crossref, Indexed at

5. Qin, Kang, Lingzhi Hong, Jianjun Zhang and Xiuning Le. "MET amplification as a resistance driver to TKI therapies in lung cancer: Clinical challenges and opportunities." Cancers 15 (2023): 612.

   Google Scholar, Crossref, Indexed at

6. Cecchi, Fabiola, Karen Rex, Joanna Schmidt and Cathy D. Vocke, et al. "Rilotumumab resistance acquired by intracrine hepatocyte growth factor signaling." Cancers 15 (2023): 460.

   Google Scholar, Crossref, Indexed at